Rezvilutamide Plus Abiraterone for Metastatic Hormone-sensitive Prostate Cancer

Exclusion Criteria

• •1. Failure to sign an informed consent form;
• •2. Patients with allergic reactions to the pharmaceutical ingredients or excipients used in the study;
• •3. Patients with difficulty swallowing or poor digestion and absorption function；
• •4. Patients with severe liver function impairment (Child Pugh C grade)；
• •5. Confirmed by imaging, there is a brain tumor lesion; Having a history of epilepsy, or having a disease that can trigger seizures within the 12 months prior to C1D1 (including a history of transient ischemic attacks, stroke, traumatic brain injury with consciousness disorders requiring hospitalization);
• •6. Active heart disease within the first 6 months of C1D1, including severe/unstable angina, myocardial infarction, symptomatic congestive heart failure, and ventricular arrhythmias requiring medication;
• •7. Suffering from any other malignant tumor within the first 5 years of C1D1 (excluding fully remitted in situ cancer and malignant tumors that have been determined by the researchers to progress slowly);
• •8. Have a history of immunodeficiency (including HIV testing positive, other acquired or congenital immunodeficiency diseases) or a history of organ transplantation;
• •9. Subjects who are unwilling to take effective contraceptive measures during the entire study treatment period and within 30 days after the last administration;
• •10. According to the judgment of the investigator, there are concomitant diseases (such as poorly controlled hypertension, serious diabetes, neurological or mental diseases, etc.) or any other conditions that seriously endanger the safety of patients, may confuse the research results, or affect the completion of the study by the subjects;
• •11. Patients participating in other clinical trial studies; After evaluation by the researcher, any other circumstances deemed unsuitable for participation in this study.